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Abstract
Objective: According to previous EEG reports of indicative disturbances in Alpha and Beta activities, a systematic search for
distinct EEG abnormalities in a broader population of Ecstasy users may especially corroborate the presumed specific
neurotoxicity of Ecstasy in humans.
Methods: 105 poly-drug consumers with former Ecstasy use and 41 persons with comparable drug history without Ecstasy
use, and 11 drug naives were investigated for EEG features. Conventional EEG derivations of 19 electrodes according to the
10-20-system were conducted. Besides standard EEG bands, quantitative EEG analyses of 1-Hz-subdivided power ranges of
Alpha, Theta and Beta bands have been considered.
Results: Ecstasy users with medium and high cumulative Ecstasy doses revealed an increase in Theta and lower Alpha
activities, significant increases in Beta activities, and a reduction of background activity. Ecstasy users with low cumulative
Ecstasy doses showed a significant Alpha activity at 11 Hz. Interestingly, the spectral power of low frequencies in medium
and high Ecstasy users was already significantly increased in the early phase of EEG recording. Statistical analyses suggested
the main effect of Ecstasy to EEG results.
Conclusions: Our data from a major sample of Ecstasy users support previous data revealing alterations of EEG frequency
spectrum due rather to neurotoxic effects of Ecstasy on serotonergic systems in more detail. Accordingly, our data may be
in line with the observation of attentional and memory impairments in Ecstasy users with moderate to high misuse. Despite
the methodological problem of polydrug use also in our approach, our EEG results may be indicative of the
neuropathophysiological background of the reported memory and attentional deficits in Ecstasy abusers. Overall, our
findings may suggest the usefulness of EEG in diagnostic approaches in assessing neurotoxic sequela of this common drug
abuse.
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Introduction
Since the late 1980s, Ecstasy has been especially known in the
so-called ‘‘techno’’-scene as a recreational drug due to its specific
psychotropic effects, characterized in psychopharmacologic terms
as an entactogen. However, numerous hazards related to this drug
and its substantial compounds as 3,4-Methylenedioxymethamphe-
tamine (MDMA) have been disclosed. Besides various medical and
diverse psychiatric disturbances, there is striking evidence for
cognitive impairments such as memory and attention associated
with Ecstasy use [1–5].
In regard to research findings in animal models, MDMA as the
principal compound of Ecstasy revealed neurotoxic effects
predominantly in serotonergic structures of the central nervous
systems (CNS) with no or incomplete regeneration in neocortical
as well as other distinct brain structures like the limbic system [6–
9]. More precisely, neuroimaging approaches in humans like
positrone emission tomography (PET) and functional MRI, or
cerebrospinal fluid (CSF) analysis support clear evidence of specific
neurotoxicity effects of Ecstasy consumers in the serotonergic
system [2,10]. More interestingly for our approach, EEG data
from subjects with poly-drug abuse including recent Ecstasy
use showed disturbances in brain function with altered activities
in the Alpha and lower Beta band, but, moreover, a reduced
interhemisperic EEG coherence [11]. Several reports of EEG
analyses and brainstem acoustic evoked potentials (BAEP) mainly
pointing to neuropathophysiological changes among Ecstasy users,
indicating a selective neurotoxicity within the serotonergic system
of the CNS [12–15]. Among the numerous serotonergic and
noradrenergic neurotransmitter systems, primarily 5-HT-specific
projections from the raphe nuclei to thalamic, hypothalamic and
hippocampal areas, and furthermore to the visual, frontal and
temporal visual association cortices, are considered a central
potential target [16,17]. 5-hydroxytryptamin is mainly synthesized
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different functions like wake-sleep-rhythm, behavioural arousal,
and attention [17]. Thus, disturbances of these functions due to
selective neuropathogeneity of Ecstasy may be expected. Although
numerous clinical reports support the neuroanatomical back-
ground for Ecstasy neurotoxicity in humans, published data are
still incomplete and controversial, partly because of methodolog-
ical restrictions [18].
According to the still prominent and robust neurophysiologic
findings in Ecstasy users, the aim of the present study was to detect
whether EEG activity is altered in an extended representative
sample of former Ecstasy users. The present study, as part of a great
investigation for registering pathological features of Ecstasy
consumption, intends to enlighten the discussion whether distur-
bances of serotonergic pathways due to neurotoxic effects of the
principal components of Ecstasy commonly distributed within
European areas are disclosable in neuroimaging techniques such as
the EEG. If so, the EEG comfortable for neurophysiological
requests everywhere may be recommendable at least in diagnostic
approaches to calculate neurotoxicologic effects of Ecstasy in
suspected humans.
Materials and Methods
Subjects
The study was conducted for investigation on permanent
sequelae of Ecstasy use in subjects associated with the ‘‘techno-
scene’’. This investigation aimed to identify psychological and
physical health risks of Ecstacy and to develop a risk-classification
scheme for certain subgroups of polydrug users. In regard to a
mutidisciplinary study concept, the present study focused the
investigation of possible alterations of certain EEG variables
according to Ecstasy misuse.
One-hundred and fifty-seven men and women were enrolled in
this study. One-hundred and five subjects had ingested variable
quantities of Ecstasy in addition to the use of ‘‘typical drugs’’ like
amphetamines, hallucinogenes, cannabinoids and cocaine in
various combinations. Forty-one subjects served as controls for
the Ecstasy users, i.e. they had similar patterns of polydrug use, but
had never ingested Ecstasy. A second control group of eleven
subjects had never ingested any drugs, termed drug naives. For
estimation of dose-effect-relationships, the Ecstacy user group was
divided into three subgroups according to the cumulative total
amount of Ecstacy tablet ingestion: 1–99 tablets defined ‘‘tasting
users’’, 100–499 tablets defined ‘‘occasional users’’, and 500 or
more ‘‘permanent users’’, respectively. Substantial inclusion
criteria was the relationship to the ‘‘techno scene’’. Subjects were
recruited mainly by inquiries in well known locations of the
‘‘techno’’-scene of Hamburg, Germany. All enrolled subjects were
examined clinically and checked for internal, neurologic and
psychiatric disorders as exclusion criteria.
Laboratory analyses of hair samples were performed to validate
the self-reported drug history. Details on drug history and
toxicologic laboratory investigations are already published else-
where [19,20]. All participants were informed about design and
background of the study, and gave written consent, as approved by
the local ethics committee of the Medical Facility at the University
of Hamburg, Germany. This procedure was constituted and
considered without any exceptions in regard to the Declaration of
Helsinki.
Procedures
Ten minutes of resting EEG were employed for statistical
evaluation. Two minutes with photostimulation and three minutes
with hyperventilation were also recorded for clinical assessment of
lowered seizure threshold. 19 electrodes recording in a configu-
ration according to the standard 10-20-system was applied.
Analogue measurements of EEG signals were performed with a
time constant of 10 s, and the sampling rate was 256 per second.
For analysis of EEG power spectra, artefact-free sequences of at
least two seconds were used. The power spectra were restricted to
the standard band ranges in electroencephalography: Delta: 0.5–
3.5 Hz, Theta: 3.5–7.5 Hz, Alpha: 7.5–13.5 Hz und Beta: 13.5–
30.0 Hz. Special variables were formed for a closer differentiation
of possible shifts to slower or faster activities: Theta 1: 3.5–5.0 Hz,
Theta 2: 5.0–7.5 Hz, Alpha 1: 7.5–9.0 Hz, Alpha 2: 9.0–11.0 Hz,
Alpha 3: 11.0–13.5 Hz; Beta 1: 13.5–20.0 Hz, Beta 2: 20.0–
22.0 Hz; Beta 3: 22.0–30.0 Hz. Power computation was drawn
from occipital (O1, O2) and parasagittal (F3, F4; C3, C4; P3, P4)
channels. Spectral power in the Alpha band was further analyzed
at 0.5, and Theta ranges at 1.0 Hz intervals. Finally, lower Alpha-
and sub-Alpha-power during the first two minutes of EEG
acquisition were compared. Delta activity was only assessed from
qualitative EEG because of the high amount of artifacts.
EEG recordings and analyses of power spectra were conducted
with the Neurofile system by Nihon Kohden (V2.91; Japan).
Calculation of digital data from the 2-sec-epochs were conducted
with a digitalizing rate of 256 per second.
Statistical analysis
Analysis of Variance (ANOVA) was applied in calculating the
differences of the defined EEG bands in quantitative EEG, thus
analysing each EEG data for all groups of Ecstasy and non-Ecstasy
usage. Furthermore, Analysis of Covariance (ANCOVA) was em-
ployed for the effects of concomitant drugs. Associations were
estimated by Pearson’s correlation. Differences between groups were
assessed by the post hoc Scheffe ´-test (90% resp. 95% confidence
interval for two-way testing). P-values #0.05 and #0.01 were
considered as significant and highly significant, respectively.
Results
157 female and male subjects with a mean age of 22 years (+3.70)
were enrolled in this study. 101 subjects had a history of Ecstasy
consumption, and the median time range of abstinence from Ecstasy
wasaround5months(3daysminimal,8yearsmaximal).9userswith
a total ingestion of less than 100 Ecstasy tablets were abstinent on an
average of 9.8 months, 56 users with 100 up to 499 tablets on an
average of 3.0 months, and 36 users with more than 500 tablets on
an average of 3.4 months, respectively. 41 subjects with a com-
parable polysubstance use of common drugs like cannabis, cocaine
and amphetamines, but without Ecstasy, represent drug controls.
Furthermore, 11 subjects had not had any experiences with illicit
drugs, thus representing drug naives (see table 1). Subjects with a
medium and severe Ecstasy ingestion behaviour yielded a higher
ingestion rate of other illicit drugs in subjects. Control subjects with a
polysubstance use were quite comparable in their consumption
behaviour of cannabis ingestion, whereas remaining drugs were less
frequently represented in this control group. Noteworthy in regard to
the assessments of each participant, toxicologic analyses of hair sam-
ples revealed an agreement of 91.3% to self-reported drug history.
Comparing the conventional EEG activity bands of Ecstasy
users with controls, high Ecstasy users showed a significant
increase of power for Beta bands (F 3.41; p=0.029). Moreover,
medium and high Ecstasy users yielded an augmentation of slow
frequencies in the Theta range (nonsignificant). Low Ecstasy users
revealed a trend to the faster Alpha subband, whereas high Ecstasy
users showed a trend to lower Alpha subband.
EEG Features of Ecstasy Abuse
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subdivided by 0.5 Hz steps, a dominant frequency at 9 Hz among
medium Ecstasy users was detected (see figure 1). High Ecstasy
users and poly-drug users with no history of Ecstasy showed a peak
at 9.5 Hz, while low Ecstasy users showed a peak of dominant
frequency at 11 Hz (F 3.87; p=.001).
Table 1. Prevalences of drug misusers and their consumptions.
Psychotropic substances Polysubstance use with Ecstasy consume Controls
all
N=101
tasting users
N=9
occasional users
N=56
permanent users
N=36
polysub-stance use
without Ecstasy
consume
N=41
drug naives
N=11
prevalences 3 06 1 23 0 6 1 2 3 06 1 23 06 1 23 06 1 23 06 1 2
Ecstasy 5 6 7 4 8 4 2 2 5 6 5 6 6 4 7 9 8 8 5 3 7 2 8 9 ------
Alcohol 7 88 78 71 0 01 0 01 0 07 18 08 08 39 49 49 49 49 46 49 39 3
Cannabis 59 70 75 44 67 89 61 75 77 61 61 69 75 86 86 - - 7
Amphetamines 2 85 26 2- 1 1 2 2 2 75 46 33 66 17 23 8 1 1- - -
Cocaine 34 61 67 11 44 44 36 59 70 36 69 69 11 22 22 - - -
Halluzinogenes 16 33 50 11 11 22 18 38 50 14 31 56 3 6 11 - - -
Heroine 223- - - 445- - - - -----
other Opiates
or Analgesics
--1 - - - --2 ---------
Sedatives 466- 1 11 1555366- -----
Sniffle substances 281 2 - - - 471 1 - 1 1 1 7 333- - -
Other drugs 7 1 62 4- - - 1 12 02 73 1 42 5- - 8 - - -
30-day-prevalence (30), 6-months-prevalence (6) and 12-months-prevalence (12) of drug consumption regarding differences in group and consumption order (results in
percentage).
doi:10.1371/journal.pone.0014097.t001
Figure 1. EEG subbands of Alpha and Theta activities in regard to drug consumption order. Histogram of spectral power by
electroencephalographic frequency in 1.0 Hz steps within the Theta-band, and in 0.5 Hz steps within the Alpha-band, according to groups of
polydrug-users with and without Ecstasy consumption and drug naives, in a study cohort of 146 polydrug-users and 11 drug naives as controls.
doi:10.1371/journal.pone.0014097.g001
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recording, medium and high Ecstasy users yielded increased
power for lower Alpha (F 2.98; p=.047) and upper Theta ranges
(F 3.01; p=0.014) (see figure 2).
We found a positive correlation between categorized Ecstasy
consumption and an increase of 5 Hz and, within the first two
minutes of EEG recording, the low Alpha and upper Theta
subband spectral power (see table 2).
Analysis of covariates (ANCOVA) found a significant main
impact of Ecstasy and no relevant impact of other concurrent
drugs (Amphetamines, Cannabinoides, Hallucinogenes, Cocaine)
on the above mentioned changes in spectral power (F-value for
Ecstasy at 5 Hz 5.48; p=.006, at 9.5 Hz F=3.51; p=.034, at
11.0 Hz F=6.06; p=.003). During the first two minutes of EEG
recording, the effect of Ecstasy on the upper Theta subband power
approximated statistical significance (F 2.95; p=.057).
Discussion
Principalfindings of ourstudy werean increase inabsolute power
of Beta, low Alpha and Theta activities in association with a marked
decrease in the frequency of dominant activity in Ecstasy users with
Figure 2. Comparison of lower Alpha and upper Theta activities of the first two minutes of recording. Spectral power of upper Theta-
band (theta-2, i.e. 5.0–7.5 Hz) compared with lower Alpha-band (alpha-1, i.e. 7.5–9.0 Hz) by groups of polydrug-users with and without Ecstasy
consumption and drug naives (abbreviations coded as in figure 1) during the first 2 minutes of EEG registration.
doi:10.1371/journal.pone.0014097.g002
Table 2. Overview of correlative effects of consumed drugs and EEG variables.
Variables of EEG//Drugs 5.0 Hz 9.0 Hz 9.5 Hz Theta-2/2 minutes Alpha-1/2 minutes
Ecstasy 0.240
(.002)
0.144
(.071)
0.152
(.059)
0.204
(.010)
0.231
(.004)
Cannabinoides 20.048
(.562)
20.070
(.398)
20.037
(.657)
20.085
(.305)
20.064
(.438)
Hallucinogenes 20.029
(.792)
20.076
(.491)
20.121
(.273)
0.003
(.980)
0.008
(.944)
Amphetamines 20.037
(.712)
20.058
(.565)
20.083
(.409)
20.070
(.482)
20.035
(.727)
Cocaine 20.013
(.897)
20.056
(.575)
20.50
(.621)
20.021
(.838)
0.052
(.606)
Correlation coefficients for selected spectral bands from quantitative EEG by drug categories in a sample of 105 polydrug-users including Ecstasy use (Pearson’s
correlation, p-value in parentheses); 5.0; 9.0; and 9.5 Hz indicates spectral power at discrete EEG frequency band; Theta-2 and Alpha-1 of first 2 minutes indicates
spectral power of 5.0 up to 7.5 Hz for Theta-2, and 7.5 up to 9.0 Hz for Alpha-1.
doi:10.1371/journal.pone.0014097.t002
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servation of increases of low Alpha and Theta activities was already
pronounced at the early recording session. A dose-dependent
increase was found around 5 and 20 Hz in subjects with a medium
to high Ecstasy use. Another interesting finding was a strong power
of Alpha activity at 11 Hz in Ecstasy users with low life-time
dosages, assuming a normal EEG. Any influences of other sedative
or stimulating drugs such as cannabis, amphetamines or hallucino-
genes may be ruled out by ANCOVA. Furthermore, no other
typical EEG patterns suggesting toxic effects on the CNS, such as
generalized slowing, rhythmic delta activity or triphasic complexes,
were observed. These results are in line with former EEG studies
using similar designs [11,12,14].
The results may support the assumption of a specific neurotox-
icity of Ecstasy and its frequent compound MDMA to serotonergic
neurotransmission systems in human CNS. In addition to nor-
adrenergic and dopaminergic neuronal circuits between brainstem
and midbrain structures, like the locus coeruleus, the median
forebrain bundle and its bidirectional connections to posterior and
forebrain areas, serotonergic neurotransmission is of special interest
in regard to the sleep-wake-rhythm and vigilance regulation
[17,21]. Indeed, disturbed serotonergic neurotransmission may
result in increases of Theta and low Alpha activities in EEG [17].
The assumption that Ecstasy contributes substantially to our EEG
findings may be additionally supported by data on selective
serotonin reuptake inhibitors like fluoxetine, showing a close
relationship between the activities of serotonergic transmitting
systems and changes in Alpha and Beta spectra, accompanied with
clinical statesofawakeness[22,23].Specificserotonergic projections
of the dorsal and median raphe nucleus to hypothalamic, frontal
and occipital areas are affected by neurotoxic agents like Ecstasy,
and, therefore, are implemented in modulating attention, memory
and executive tasks [24,25]. Therefore, a linking of the neurobio-
logic and neurophysiologic approach appears more reasonable
[4,26]. Thus, the clinical impact of these well reported altered EEG
activities and our findings have to be considered with special
interest. Clinical EEG research underscores the crucial relevance of
vigilance regulation networks for high order cognitive and affective
functions [21,27]. A more recent study did indeed hallmark a strong
impact of observed vigilance dynamics in EEG to fMRI signals,
which are quite in agreement for certain cognition procedures and
its topographic brain areas, in particular the frontal and temporal
cortices [28]. However, although McKenna recognized vigilance
disturbances in EEG recordings among Ecstasy users [29], specific
analyses have not been performed so far. This neglect of analysing
EEG data more precisely on this topic may be due to the particular
consideration of results obtained with newer neuroimaging tech-
niques such as cerebral PET or MRI and its previous elucidative
positive correlations to cognitive and also to emotional dysfunctions
in humans with a long-term abuse of Ecstasy [2,20].
Thomasius in his first major search for neurotoxic sequela in
one-hundred and five long time Ecstasy users, of which our EEG
recordings were obtained, found several neuropsychiatric sequela,
which have been already published elsewhere [19]. Interestingly,
subjects with a medium and high Ecstasy use showed impairments
in short term and working memory, confirming previous results
of cross-sectional as well as longitudinal studies of cognitive
impairment in Ecstasy users in different neuropsychological and
imaging approachments [1,4,30]. Although we did not compare
our EEG data with the obtained neuropsychologic data of
Thomasius’ approach in more detail due to editorial restrictions,
our EEG findings may correspond to these particular memory
disturbances due to Ecstasy misuse [31–33]. In this line, the in-
creased power in Theta band in medium and high Ecstasy users
may indicate functional alterations in hypothalamus or hippo-
campus, though parahippocampal and the medial frontal and
posterior regions could be shown as highly correlated to
subsequent memory-dependent Theta power in EEG [24,34,35].
This assumption is supported by learning and memory dysfunc-
tions and aberrant regeneration in monkeys exposed to Ecstasy
compounds [8,34]. In healthy humans, increase of low frequencies
in EEG show a clear correlation with decline of sustained
attention, which is necessary in preceding memory efforts [25].
Like most previous studies on persisting effects of Ecstasy in
humans, our study is subject to the methodological problem of
polydrug use. However, pure Ecstasy users are still rare; therefore,
investigations of isolated Ecstasy effects have been unsuccessful
and do not appear feasible [13,18,30]. By investigating a quite
large sample of Ecstasy users, our analyses still reached a stronger
statistical power compared to previous publications. Moreover,
accounting for possible interactions with concurrent drugs
ascertained the effect of Ecstasy on EEG spectral changes.
Common recreational drugs like alcohol, psychotropic stimulants
or cannabis usually do not yield EEG patterns as found in our
study. In particular, these CNS active drugs such as cannabis with
its well-recognized risk factor for neuropsychiatric and neuropsy-
chologic disorders are quite removed from the pathophysiologic
pathway of Ecstasy, as shown for cannabinoids with its
neuroprotective actions and especially its blocking properties of
MDMA-induced neurotoxicity in laboratory animals [27]. Nev-
ertheless, one may argue that a specific influence of serotonin as
well as disturbed serotonergic pathways due to selective toxic
agents such as MDMA could not be detected in neurophysiologic
procedures such as EEG. This objection seems to be unjustified,
though our EEG findings are well in line with previous EEG
investigations of human Ecstasy consumers in different fashions
[11,14]. The lower specificity of EEG in focusing selected
neurotransmitter systems, especially the serotonergic, and their
relationships to functional neuronal networks represents a
common disadvantage in all neuroimaging techniques. We still
favoured the EEG due to its flexibility in analysing the EEG power
in more detail, as it is well accepted in neuroscientific research
capturing features of brain disturbances in regard to toxicologic
effects as noted for Ecstasy and its frequent compounds. Moreover,
analysis of covariate influences of concomitant drugs to altered
EEG power in our study yielded a main effect for Ecstasy as the
principal contributing variable. We also did not conduct specific
genetics analysis, in particular serotonin receptor or transporter
mechanisms in identifying special polymorphisms, which may
contribute to our study. Nevertheless, these very new aspects in
studying serotonin pathways have also not been considered in
other comparable study designs, but further studies implementing
these exciting approaches in pathophysiologic Ecstasy neurotox-
icity aspects are anxiously awaited.
Besides the clinical avenues such as neuropsychological
inventories, further investigations with a longitudinal design
proving lasting Ecstasy effects on EEG in polydrug users are of
special interest and may be beneficial for the ongoing discussion of
the neurotoxicity particularly of common substances of Ecstasy in
humans [36]. Neurophysiologic approaches in investigating the
neurotoxicity of Ecstasy in humans are of highly promising value,
in particular linking the frequent observation of disturbed skills like
working memory and attention.
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